No Data
Express News | fosun pharma's Red Flag Pharmaceutical's drug-resistant tuberculosis pharmaceutical Pruneil approved for market launch
Shanghai Fosun Pharmaceutical Gets Drug Registration for Pertuzumab Biosimilar
Fosun Pharma (02196.HK) has received approval to start clinical trials for its solid tumor treatment drug in mainland China.
Fosun pharma (02196.HK) announced that its holding subsidiary Shanghai henlius biotechnology and its holding subsidiary (collectively referred to as "henlius") recently received approval from the National Medical Products Administration for the initiation of phase Ib/II clinical trials of HLX43 for injection, either as monotherapy or in combination, for the treatment of advanced/metastatic solid tumors. Henlius plans to conduct relevant clinical trials of this new drug in china when conditions allow. Fosun pharma stated that the new drug is a novel DNA topoisomerase I inhibitor small-molecule toxin-peptide linker licensed from Suzhou Yilian biomedical, in combination with the group’s independently developed targets.
Fosun Pharma (02196.HK) has received approval to conduct clinical trials for cancer treatment drugs in mainland China.
Fosun Pharma (02196.HK) announced that its holding subsidiary Shanghai Henlius Biotech and its subsidiaries (collectively referred to as "Henlius") have recently received approval from the National Medical Products Administration for conducting clinical trials on HLX22 in combination with trastuzumab and chemotherapy, or in combination with deruxtecan for treating HER2-expressing solid tumors. Henlius plans to conduct the Phase II clinical trial of this new drug in China once conditions are met. Fosun Pharma stated that HLX22 involved in these treatment regimens is a novel targeted HER2 developed independently by the group through licensing from AbClon, Inc.
The clinical trial application for HLX43 injection by henlius (02696.HK) has been approved.
Henlius (02696.HK) announced that the clinical trial application for HLX43 (a targeted PD-L1 antibody - a novel DNA topoisomerase I inhibitor conjugate) for single-agent or combination treatment of advanced/metastatic solid tumors in a phase 1b/2 clinical trial has been approved by the National Medical Products Administration. The company plans to conduct clinical trials for related indications in china once conditions permit. HLX43 is a targeted therapy developed by the company using a novel DNA topoisomerase I inhibitor small molecule toxin - peptide linker introduced from Suzhou Yilian biomedical, coupled with the company's independently developed targeted PD-L1 antibody.
Fosun Pharma (02196): Henlius has received approval from the National Medical Products Administration to conduct clinical trials for HLX22 in combination with trastuzumab and chemotherapy or in combination with deruxtecan for the treatment of HER2-express
Fosun Pharma (02196) announced that the company's controlling subsidiary, Henlius Biotech Inc., based in Shanghai, ...
